Oncogenic KRAS is one of the most common drivers of human cancer. Despite intense research, no effective therapy to directly inhibit oncogenic KRAS has yet been approved and KRAS mutant tumors remain associated with a poor prognosis. This short review discusses the current knowledge of the redox regulation of RAS and examines the newest findings on cysteine 118 (C118) as a potential novel target for KRAS inhibition.

中文翻译：

---

KRAS氧化还原调控的发现

致癌 KRAS 是人类癌症最常见的驱动因素之一。尽管进行了大量研究，但尚未批准直接抑制致癌 KRAS 的有效疗法，并且 KRAS 突变肿瘤仍然与不良预后相关。这篇简短的综述讨论了 RAS 氧化还原调节的当前知识，并检查了半胱氨酸 118 (C118) 作为 KRAS 抑制的潜在新靶点的最新发现。